NASDAQ$VERV

Verve Therapeutics Inc · Q4 2025 earnings

Q4 2025 earnings · · Before market open · Investor relations

Reports awaiting report

Verve Therapeutics hasn't published Q4 2025 actuals yet. The tiles below frame what to compare against; sections further down are historical context only.

  • Most recent report

    Q1 2025

    Revenue
    $33M
    EPS
    -$0.35
  • FY2025 consensus

    Analyst consensus

    Revenue
    $15.1M
    EPS
    -$2.75

Revenue & EPS history

Verve Therapeutics · Revenue · Quarterly

$33M

Q1 2025+479%vs Q1 2024
Beat estimate in 10 of 10 quarters(100%)
ActualEstimate

Historical revenue by segment

Verve Therapeutics · $3.12M total across 1 segment · Q3 2023

  • Collaboration Revenue
    $3.12M—

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 17 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-1.0%

Avg return

Earnings day

+0.3%

Avg return

5 days after

-3.8%

Avg return

30 days after

47%

8 / 17 earnings

Positive

+24.4%

Q4 2023

Best reaction

-34.2%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2025———
Q1 2025+3.4%+5.0%+48.1%
Q4 2025-1.7%-2.9%-16.3%
Q3 2024+6.0%+4.5%+1.0%
Q2 2024-12.1%-20.8%-1.6%
Q1 2024+3.2%+0.8%-15.6%
Q4 2023+24.4%+12.7%-8.2%
Q3 2023+11.8%+4.8%-13.8%
Q2 2023+2.6%-9.9%-28.0%
Q1 2023-5.2%-4.5%-2.6%
Q4 2022+7.0%+3.0%-20.8%
Q3 2022-34.2%-13.7%-31.5%
Q2 2022+17.5%+31.2%+47.0%
Q1 2022-4.4%+12.8%+15.2%
Q4 2021-20.1%-4.3%-19.7%
Q3 2021-2.7%-7.8%-34.7%
Q4 2020-1.4%+5.5%+7.5%
Q2 2021-10.7%-11.9%+10.1%
Q1 2021———
Q3 2020———
Q2 2020———
Q1 2020———

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro